Authors : Langouo Fontsa M, Padonou F, Willard-Gallo K Year : 2022 Journal : Curr Opin Oncol
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial.
Authors : Schwarze JK, Garaud S, Jansen YJL, Awada G, Vandersleyen V, Tijtgat J, de Wind A, Kristanto P, Seremet T, Willard-Gallo K, Neyns B Year : 2022 Journal : Cancers (Basel)
Characterization of Immunoactive and Immunotolerant CD4+ T Cells in Breast Cancer by Measuring Activity of Signaling Pathways That Determine Immune Cell Function.
Authors : Wesseling-Rozendaal Y, van Doorn A, Willard-Gallo K, van de Stolpe A Year : 2022 Journal : Cancers (Basel)
A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.
Authors : Gourari K, Catherine J, Garaud S, Kerger J, Lepida A, Georgala A, Lebrun F, Gomez Galdon M, Gil T, Willard-Gallo K, Langouo Fontsa M Year : 2022 Journal : Diagnostics (Basel)
T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy.
Authors : Garaud S, Dieu-Nosjean MC, Willard-Gallo K Year : 2022 Journal : Nat Commun